Molecular Signatures of Hemagglutinin Stem-Directed Heterosubtypic Human Neutralizing Antibodies against Influenza A Viruses

English version České info

The quest for universal influenza vaccine has gained wide interest with the discovery of human neutralizing antibodies that are able to variably cross neutralize and protect against different influenza strains, subtypes, groups and lineages. These antibodies, which bind to a highly conserved epitope in the hemagglutinin stem, are often encoded by rearranged IGHV1-69 germline genes that alone make contact with HA and prevent virus entry and emergence of escape mutants. Our study was undertaken to gain an understanding of what structural requirements enable a rearranged IGHV1-69 Ab to become a potent cross-neutralizing antibody. We found that in addition to a critical amino acid triad consisting of a pair of anchor residues in CDR-H2 and a properly positioned CDR-H3 Tyr, distinctive V-segment substitutions that arise in positions that are distinct from phase I AID somatic hypermutation (SHM) hotspot motifs are often required. As few as two V-segment SHM can fulfill this role which appears to facilitate the optimal binding of CDR-H2 Phe54 and CHR-H3-Tyr into adjacent hydrophobic pockets in the HA stem. These studies provide new information on the SHM requirements for IGHV1-69-encoded B cells to produce HV1-69-sBnAbs and suggest that there may exist alternative routes to their elicitation by vaccination.

Vyšlo v časopise: Molecular Signatures of Hemagglutinin Stem-Directed Heterosubtypic Human Neutralizing Antibodies against Influenza A Viruses. PLoS Pathog 10(5): e32767. doi:10.1371/journal.ppat.1004103
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004103

Souhrn

Zdroje

1. SuiJ, HwangWC, PerezS, WeiG, AirdD, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16 : 265–273.

2. KashyapAK, SteelJ, OnerAF, DillonMA, SwaleRE, et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 105 : 5986–5991.

3. ThrosbyM, van den BrinkE, JongeneelenM, PoonLL, AlardP, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.

4. EkiertDC, BhabhaG, ElsligerMA, FriesenRH, JongeneelenM, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324 : 246–251.

5. EkiertDC, FriesenRH, BhabhaG, KwaksT, JongeneelenM, et al. (2011) A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333 : 843–850.

6. CortiD, VossJ, GamblinSJ, CodoniG, MacagnoA, et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333 : 850–856.

7. DreyfusC, LaursenNS, KwaksT, ZuijdgeestD, KhayatR, et al. (2012) Highly conserved protective epitopes on influenza B viruses. Science 337 : 1343–1348.

8. NakamuraG, ChaiN, ParkS, ChiangN, LinZ, et al. (2013) An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 14 : 93–103.

9. FriesenRH, LeePS, StoopEJ, HoffmanRM, EkiertDC, et al. (2014) A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S A 111 : 445–450.

10. CortiD, SuguitanALJr, PinnaD, SilacciC, Fernandez-RodriguezBM, et al. (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120 : 1663–1673.

11. WrammertJ, KoutsonanosD, LiGM, EdupugantiS, SuiJ, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208 : 181–193.

12. ThomsonCA, WangY, JacksonLM, OlsonM, WangW, et al. (2012) Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. Front Immunol 3 : 87.

13. LiGM, ChiuC, WrammertJ, McCauslandM, AndrewsSF, et al. (2012) Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A 109 : 9047–9052.

14. SuiJ, SheehanJ, HwangWC, BankstonLA, BurchettSK, et al. (2011) Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis 52 : 1003–1009.

15. PicaN, HaiR, KrammerF, WangTT, MaamaryJ, et al. (2012) Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A 109 : 2573–2578.

16. MillerMS, TsibaneT, KrammerF, HaiR, RahmatS, et al. (2013) 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis 207 : 98–105.

17. BoydSD, GaetaBA, JacksonKJ, FireAZ, MarshallEL, et al. (2010) Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements. J Immunol 184 : 6986–6992.

18. GlanvilleJ, KuoTC, von BudingenHC, GueyL, BerkaJ, et al. (2011) Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation. Proc Natl Acad Sci U S A 108 : 20066–20071.

19. SchroederHWJr, HillsonJL, PerlmutterRM (1987) Early restriction of the human antibody repertoire. Science 238 : 791–793.

20. SassoEH, Willems van DijkK, BullAP, MilnerEC (1993) A fetally expressed immunoglobulin VH1 gene belongs to a complex set of alleles. J Clin Invest 91 : 2358–2367.

21. MilnerEC, HufnagleWO, GlasAM, SuzukiI, AlexanderC (1995) Polymorphism and utilization of human VH Genes. Ann N Y Acad Sci 764 : 50–61.

22. HarrisAK, MeyersonJR, MatsuokaY, KuybedaO, MoranA, et al. (2013) Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc Natl Acad Sci U S A 110 : 4592–4597.

23. VictoraGD, NussenzweigMC (2012) Germinal centers. Annu Rev Immunol 30 : 429–457.

24. CeruttiA, ColsM, PugaI (2013) Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 13 : 118–132.

25. MeirelesLM, DomlingAS, CamachoCJ (2010) ANCHOR: a web server and database for analysis of protein-protein interaction binding pockets for drug discovery. Nucleic Acids Res 38: W407–411.

26. LingwoodD, McTamneyPM, YassineHM, WhittleJR, GuoX, et al. (2012) Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489 : 566–570.

27. WuX, ZhouT, ZhuJ, ZhangB, GeorgievI, et al. (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333 : 1593–1602.

28. PeledJU, KuangFL, Iglesias-UsselMD, RoaS, KalisSL, et al. (2008) The biochemistry of somatic hypermutation. Annu Rev Immunol 26 : 481–511.

29. RogozinIB, PavlovYI, BebenekK, MatsudaT, KunkelTA (2001) Somatic mutation hotspots correlate with DNA polymerase eta error spectrum. Nat Immunol 2 : 530–536.

30. ClarkLA, GanesanS, PappS, van VlijmenHW (2006) Trends in antibody sequence changes during the somatic hypermutation process. J Immunol 177 : 333–340.

31. AlmagroJC, BeaversMP, Hernandez-GuzmanF, MaierJ, ShaulskyJ, et al. (2011) Antibody modeling assessment. Proteins 79 : 3050–3066.

32. CortiD, LanzavecchiaA (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31 : 705–742.

33. SassoEH, JohnsonT, KippsTJ (1996) Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. J Clin Invest 97 : 2074–2080.

34. HanT, MarascoWA (2011) Structural basis of influenza virus neutralization. Ann N Y Acad Sci 1217 : 178–190.

35. KuchenS, RobbinsR, SimsGP, ShengC, PhillipsTM, et al. (2007) Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol 179 : 5886–5896.

36. VinuesaCG, LintermanMA, GoodnowCC, RandallKL (2010) T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev 237 : 72–89.

37. SchwickertTA, VictoraGD, FooksmanDR, KamphorstAO, MugnierMR, et al. (2011) A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. J Exp Med 208 : 1243–1252.

38. PugaI, ColsM, BarraCM, HeB, CassisL, et al. (2012) B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol 13 : 170–180.

39. KeatingR, HertzT, WehenkelM, HarrisTL, EdwardsBA, et al. (2013) The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol 14 : 1266–1276.

40. WeiCJ, YassineHM, McTamneyPM, GallJG, WhittleJR, et al. (2012) Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci Transl Med 4 : 147ra114.

41. GoffPH, EgginkD, SeibertCW, HaiR, Martinez-GilL, et al. (2013) Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One 8: e79194.

42. EgginkD, GoffPH, PaleseP (2014) Guiding the Immune Response against Influenza Virus Hemagglutinin toward the Conserved Stalk Domain by Hyperglycosylation of the Globular Head Domain. J Virol 88 : 699–704.

43. KrammerF, PaleseP (2013) Universal influenza virus vaccines: need for clinical trials. Nat Immunol 15 : 3–5.

44. JardineJ, JulienJP, MenisS, OtaT, KalyuzhniyO, et al. (2013) Rational HIV immunogen design to target specific germline B cell receptors. Science 340 : 711–716.

45. KrammerF, PicaN, HaiR, MargineI, PaleseP (2013) Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87 : 6542–6550.

46. SteelJ, LowenAC, WangTT, YondolaM, GaoQ, et al. (2010) Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1: e00018–10.

47. BommakantiG, LuX, CitronMP, NajarTA, HeideckerGJ, et al. (2012) Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J Virol 86 : 13434–13444.

48. LuY, WelshJP, SwartzJR (2014) Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Natl Acad Sci U S A 111 : 125–130.

49. PotterKN, LiY, MageedRA, JefferisR, CapraJD (1999) Molecular characterization of the VH1-specific variable region determinants recognized by anti-idiotypic monoclonal antibodies G6 and G8. Scand J Immunol 50 : 14–20.

50. FinnJA, CroweJEJr (2013) Impact of new sequencing technologies on studies of the human B cell repertoire. Curr Opin Immunol 25 : 613–618.

51. WatsonCT, SteinbergKM, HuddlestonJ, WarrenRL, MaligM, et al. (2013) Complete haplotype sequence of the human immunoglobulin heavy-chain variable, diversity, and joining genes and characterization of allelic and copy-number variation. Am J Hum Genet 92 : 530–546.

52. StudierFW (2005) Protein production by auto-induction in high density shaking cultures. Protein Expr Purif 41 : 207–234.

53. HootS, McGuireAT, CohenKW, StrongRK, HangartnerL, et al. (2013) Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs. PLoS Pathog 9: e1003106.

54. PettersenEF, GoddardTD, HuangCC, CouchGS, GreenblattDM, et al. (2004) UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem 25 : 1605–1612.

55. FahmyA, WagnerG (2011) Optimization of van der Waals energy for protein side-chain placement and design. Biophys J 101 : 1690–1698.